{
  "resourceType" : "MedicationRequest",
  "id" : "PertuzumabMedRequestPHD",
  "meta" : {
    "profile" : ["http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-request"]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: MedicationRequest PertuzumabMedRequestPHD</b></p><a name=\"PertuzumabMedRequestPHD\"> </a><a name=\"hcPertuzumabMedRequestPHD\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"http://hl7.org/fhir/us/mcode/STU4/StructureDefinition-mcode-cancer-related-medication-request.html\">Cancer-Related Medication Request Profile</a></p></div><p><b>status</b>: Draft</p><p><b>intent</b>: Order</p><p><b>medication</b>: <span title=\"Codes:{http://www.nlm.nih.gov/research/umls/rxnorm 1298944}\">pertuzumab</span></p><p><b>subject</b>: <a href=\"Patient-MOPAPatientExample.html\">Jane Smith (official) Female, DoB: 1968-04-15 ( http://hospital.example.org/patients#MRN-78432)</a></p><p><b>requester</b>: <a href=\"Practitioner-MOPAOncologistExample.html\">Practitioner Maria Lopez (official)</a></p><p><b>reasonReference</b>: <a href=\"Condition-MOPAMetastaticBreastCancerConditionExample.html\">Condition Malignant neoplasm of breast</a></p><h3>DosageInstructions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>840 mg IV cycle 1, then 420 mg IV q21d</td></tr></table></div>"
  },
  "status" : "draft",
  "intent" : "order",
  "medicationCodeableConcept" : {
    "coding" : [{
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1298944",
      "display" : "pertuzumab"
    }]
  },
  "subject" : {
    "reference" : "Patient/MOPAPatientExample"
  },
  "requester" : {
    "reference" : "Practitioner/MOPAOncologistExample"
  },
  "reasonReference" : [{
    "reference" : "Condition/MOPAMetastaticBreastCancerConditionExample"
  }],
  "dosageInstruction" : [{
    "text" : "840 mg IV cycle 1, then 420 mg IV q21d"
  }]
}